IV Ketamine for Bipolar Depression: What the New JAMA Psychiatry Study Shows
Bipolar depression has one of the shortest treatment shelf lives in psychiatry. For decades, the list of approved options has stayed thin, and most of
Bipolar depression has one of the shortest treatment shelf lives in psychiatry. For decades, the list of approved options has stayed thin, and most of
If you’ve tried two or more antidepressants and still don’t feel like yourself, you’re probably not looking for promises. You’re looking for honest answers about
If you live with both depression and a drinking problem, a dual diagnosis, you have probably heard two pieces of advice that cancel each other
The psychedelic medicine market is projected to grow from $3.63 billion in 2024 to over $10 billion by 2032, according to SNS Insider. The FDA
The race in psychedelic medicine has focused almost entirely on the molecule. Which compound wins approval first? Which trial reads out next? These are fair
Most conversations about depression and sleep stop at the obvious: people who are depressed often sleep badly. A 2026 study in Neuropsychopharmacology points somewhere deeper.
A major depressive episode can feel like standing in a room with no doors. Antidepressants may take four to six weeks to show results—and for
If you or someone you know is in crisis, confidential support is available 24/7 by calling or texting 988 (Suicide & Crisis Lifeline) or texting
On April 24, 2026, the FDA issued Commissioner’s National Priority Vouchers (CNPVs) to three companies developing psychedelic therapies for depression and PTSD. The move could
Forbes recently featured Nushama in an article exploring how psychedelic-assisted therapy could reshape the way we think about career mental health. Written by Bryan Robinson,
Bipolar depression has one of the shortest treatment shelf lives in psychiatry. For decades, the list of approved options has stayed thin, and most of
If you’ve tried two or more antidepressants and still don’t feel like yourself, you’re probably not looking for promises. You’re looking for honest answers about
If you live with both depression and a drinking problem, a dual diagnosis, you have probably heard two pieces of advice that cancel each other
The psychedelic medicine market is projected to grow from $3.63 billion in 2024 to over $10 billion by 2032, according to SNS Insider. The FDA
The race in psychedelic medicine has focused almost entirely on the molecule. Which compound wins approval first? Which trial reads out next? These are fair
Most conversations about depression and sleep stop at the obvious: people who are depressed often sleep badly. A 2026 study in Neuropsychopharmacology points somewhere deeper.
A major depressive episode can feel like standing in a room with no doors. Antidepressants may take four to six weeks to show results—and for
If you or someone you know is in crisis, confidential support is available 24/7 by calling or texting 988 (Suicide & Crisis Lifeline) or texting
On April 24, 2026, the FDA issued Commissioner’s National Priority Vouchers (CNPVs) to three companies developing psychedelic therapies for depression and PTSD. The move could
Forbes recently featured Nushama in an article exploring how psychedelic-assisted therapy could reshape the way we think about career mental health. Written by Bryan Robinson,
